- 肺癌生物靶向治疗（第2版）
- 周彩存 吴一龙 费苛
- 4548字
- 2020-08-28 13:05:29
参考文献
1.Kheifets V，Mochly-Rosen D. Insight into intra- and inter-molecular interactions of PKC：design of specific modulators of kinase function.Pharmacol Res，2007，55（6）：467-476.
2.Martiny-Baron G，Fabbro D.Classical PKC isoforms in cancer.Pharmacol Res，2007，55（6）：477-486.
3.高志强，韩宝惠.蛋白激酶C抑制剂与非小细胞肺癌的治疗.中国肺癌杂志，2009，12（1）：68-72.
4.Graham MA，Rawe I，Dartt DA，et al.Protein kinase C regulation of corneal endothelial cell proliferation and cell cycle.Invest Ophthalmol Vis Sci，2000，41（13）：4124-4132.
5.Wang JH，Redmond HP，Watson RW，et al.Involvement of tyrosine protein kinase in IFN-gamma-induced human endothelial cell apoptosis. Shock（Augusta，Ga.），1999，11（5）：311-318.
6.Regala RP，Weems C，Jamieson L，et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res，2005，65（19）：8905-8911.
7.Villalona-Calero MA，Ritch P，Figueroa JA，et al. A phaseⅠ/Ⅱ study of LY900003，an antisense inhibitor of protein kinase C-alpha，in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res，2004，10（18 Pt 1）：6086-6093.
8.Monnerat C，Henriksson R，Le CT，et al. Phase I study of PKC412（N-benzoyl-staurosporine），a novel oral protein kinase C inhibitor，combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.Annals of oncology：official journal of the European Society for Medical Oncology/ESMO.2004.15（2）：316-323.
9.Lara PN Jr，Mack PC，Synold T，et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors：a California cancer consortium phaseⅠ pharmacokinetic and molecular correlative trial.Clin Cancer Res，2005，11（12）：4444-4450.
10.Edelman MJ，Bauer KS Jr，Wu S，et al.PhaseⅠand pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res，2007，13（9）：2667-2674.
11.Winegarden JD，Mauer AM，Gajewski TF，et al.A phase Ⅱstudy of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung cancer（Amsterdam，Netherlands），2003，39（2）：191-196.
12.任伟宏，吴景兰.蛋白激酶与细胞凋亡信号及凋亡抑制信号的转导.国外医学（临床生物化学与检验学分册），2004，25（1）：79-82.
13.马强，张振书.蛋白激酶C对多药耐药调控作用.生命的化学，2001，21（4）：174-176.
14.周清华，刘伦旭，李潞，等.PKC基因在人肺癌中的转录表达.中国肺癌杂志，2000，3（5）：351-354.
15.程玺，周清华，王允，等.人非小细胞肺癌中蛋白激酶CβⅠ的表达及细胞凋亡与预后关系的研究.中国肺癌杂志，2004，7（5）：404-408.
16.高志强，杨晓华，冯久贤，等.非小细胞肺癌中蛋白激酶C-α的表达及其意义.肿瘤，2007，27（12）：981-984.
17.徐学萍，肖殿模.蛋白激酶C抑制剂的研究概况.国外医学：药学分册. 1994.21（2）：86-91.
18.Jemal A，Siegel R，Xu J，et al. Cancer statistics，2010.CA Cancer J Clin，2010，60（5）：277-300.
19.Thun MJ，Henley SJ，Burns D，et al.Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst，2006，98（10）：691-699.
20.Jemal A，Bray F，Center MM，et al. Global cancer statistics. CA Cancer J Clin，2011，61（2）：69-90.
21.Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science，1992，258（5082）：607-614.
22.Nishizuka Y.Protein kinase C and lipid signaling for sustained cellular responses. FASEB J，1995，9（7）：484-496.
23.Duquesnes N，Lezoualc’h F，Crozatier B. PKC-delta and PKC-epsilon：foes of the same family or strangers.J Mol Cell Cardiol，2011，51（5）：665-673.
24.Giorgi C，Agnoletto C，Baldini C，et al. Redox control of protein kinase C：cell- and disease-specific aspects. Antioxid Redox Signal，2010，13（7）：1051-1085.
25.Gopalakrishna R，Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med，2000，28（9）：1349-1361.
26.Kikkawa U，Kishimoto A，Nishizuka Y. The protein kinase C family：heterogeneity and its implications.Annu Rev Biochem，1989，58：31-44.
27.Svetek J，Schara M，Pecar S，et al.Spectroscopic characterization of specific phorbol ester binding to PKC-receptor sites in membranes in situ. Carcinogenesis，1995，16（10）：2589-2592.
28.Rosse C，Linch M，Kermorgant S，et al. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol，2010，11（2）：103-112.
29.Cenni V，Doppler H，Sonnenburg ED，et al. Regulation of novel protein kinase C epsilon by phosphorylation. Biochem J，2002，363（Pt 3）：537-545.
30.Pfeifhofer-Obermair C，Thuille N，Baier G. Involvement of distinct PKC gene products in T cell functions. Front Immunol，2012，3：220.
31.Zhang EY，Kong KF，Altman A. The yin and yang of protein kinase C-theta（PKCθ）：a novel drug target for selective immunosuppression.Adv Pharmacol，2013，66：267-312.
32.Quann EJ，Liu X，Altan-Bonnet G，et al.A cascade of protein kinase C isozymes promotes cytoskeletal polarization in T cells.Nat Immunol，2011，12（7）：647-654.
33.Fu G，Gascoigne NR. The role of protein kinase cηin T cell biology.Front Immunol，2012，3：177.
34.Rimessi A，Patergnani S，Ioannidi E，et al.Chemoresistance and Cancer-Related Inflammation：Two Hallmarks of Cancer Connected by an Atypical Link，PKCζ. Front Oncol，2013，3：232.
35.Breitkreutz D，Braiman-Wiksman L，Daum N，et al.Protein kinase C family：on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol，2007，133（11）：793-808.
36.Miyamae M，Rodriguez MM，Camacho SA，et al. Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption. Proc Natl Acad Sci U S A，1998，95（14）：8262-8267.
37.Benoit SC，Kemp CJ，Elias CF，et al.Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents.J Clin Invest，2009，119（9）：2577-2589.
38.Oyasu M，Fujimiya M，Kashiwagi K，et al. Immunogold electron microscopic demonstration of distinct submembranous localization of the activated gammaPKC depending on the stimulation.J Histochem Cytochem，2008，56（3）：253-265.
39.Almeida-Amaral EE，Caruso-Neves C，Lara LS，et al.Leishmania amazonensis：PKC-like protein kinase modulates the（Na++K+）ATPase activity.Exp Parasitol，2007，116（4）：419-426.
40.Rimessi A，Zecchini E，Siviero R，et al.The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells.Cell cycle（Georgetown，Tex.），2012，11（5）：1040-1048.
41.Rimessi A，Rizzuto R，Pinton P. Differential recruitment of PKC isoforms in HeLa cells during redox stress.Cell Stress Chaperones，2007，12（4）：291-298.
42.McKernan LN，Momjian D，Kulkosky J. Protein Kinase C：One Pathway towards the Eradication of Latent HIV-1 Reservoirs.Adv Virol，2012，2012：805347.
43.Steinberg SF.Structural basis of protein kinase C isoform function.Physiol Rev，2008，88（4）：1341-1378.
44.Spitaler M，Cantrell DA.Protein kinase C and beyond. Nat Immunol，2004，5（8）：785-790.
45.Rybin VO，Guo J，Harleton E，et al. Regulatory autophosphorylation sites on protein kinase C-delta at threonine-141 and threonine-295.Biochemistry，2009，48（21）：4642-4651.
46.Sadana R，Dessauer CW.Physiological roles for G protein-regulated adenylyl cyclase isoforms：insights from knockout and overexpression studies. Neurosignals，2009，17（1）：5-22.
47.Willoughby D，Cooper DM.Organization and Ca 2+ regulation of adenylyl cyclases in cAMP microdomains.Physiol Rev，2007，87（3）：965-1010.
48.Pollak MN，Schernhammer ES，Hankinson SE.Insulin-like growth factors and neoplasia. Nat Rev Cancer，2004，4（7）：505-518.
49.Oh SH，Whang YM，Min HY，et al. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.Int J Cancer，2012，131（10）：2253-2263.
50.Geraldes P，King GL. Activation of protein kinase C isoforms and its impact on diabetic complications.Circ Res，2010，106（8）：1319-1331.
51.Toton E，Ignatowicz E，Skrzeczkowska K，et al. Protein kinase Cepsilon as a cancer marker and target for anticancer therapy.Pharmacol Rep，2011，63（1）：19-29.
52.Inagaki K，Churchill E，Mochly-Rosen D.Epsilon protein kinase C as a potential therapeutic target for the ischemic heart.Cardiovasc Res，2006，70（2）：222-230.
53.Ferreira JC，Brum PC，Mochly-Rosen D. βⅡPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.J Mol Cell Cardiol，2011，51（4）：479-484.
54.Zanin-Zhorov A，Dustin ML，Blazar BR. PKC-theta function at the immunological synapse：prospects for therapeutic targeting.Trends Immunol，2011，32（8）：358-363.
55.Burguillos MA，Deierborg T，Kavanagh E，et al. Caspase signalling controls microglia activation and neurotoxicity.Nature，2011，472（7343）：319-324.
56.Zhang D，Anantharam V，Kanthasamy A，et al.Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson’s disease. J Pharmacol Exp Ther，2007，322（3）：913-922.
57.Garrido JL，Godoy JA，Alvarez A，et al.Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J，2002，16（14）：1982-1984.
58.Manji HK，Lenox RH.The nature of bipolar disorder. J Clin Psychiatry，2000，61（Supp 13）：42-57.
59.Zarate CA，Manji HK.Protein kinase C inhibitors：rationale for use and potential in the treatment of bipolar disorder.CNS Drugs，2009，23（7）：569-582.
60.Maioli E，Valacchi G.Rottlerin：bases for a possible usage in psoriasis. Curr Drug Metab，2010，11（5）：425-430. 61.Urtreger AJ，Kazanietz MG，Bal de Kier Joffe ED.Contribution of individual PKC isoforms to breast cancer progression.IUBMB Life，2012，64（1）：18-26.
62.Michie AM，Nakagawa R.The link between PKCalpha regulation and cellular transformation. Immunol Lett，2005，96（2）：155-162.
63.Sledge GW Jr，Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer.Semin Oncol，2006，33（3）：S15-18.
64.Kim J，Koyanagi T，Mochly-Rosen D. PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate，2011，71（9）：946-954.
65.Bacher N，Zisman Y，Berent E，et al.Isolation and characterization of PKC-L，a new member of the protein kinase C-related gene family specifically expressed in lung，skin，and heart.Mol Cell Biol，1991，11（1）：126-133. 66.Krasnitsky E，Baumfeld Y，Freedman J，et al.PKCη is a novel prognostic marker in non-small cell lung cancer. Anticancer Res，2012，32（4）：1507-1513.
67.Benavides F，Blando J，Perez CJ，et al. Transgenic overexpression of PKC epsilon in the mouse prostate induces preneoplastic lesions. Cell cycle（Georgetown，Tex.），2011，10（2）：268-277.
68.Dittmann K，Mayer C，Rodemann HP. Nuclear EGFR as novel therapeutic target：insights into nuclear translocation and function.Strahlenther Onkol，2010，186（1）：1-6.
69.Griner EM，Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer，2007，7（4）：281-294.
70.Meng QH，Zhou LX，Luo JL，et al.Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration. Acta Pharmacol Sin，2005，26（4）：492-499.
71.Tsai CH，Hsieh YS，Yang SF，et al. Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors：preliminary observations.Oral surgery，oral medicine，oral pathology，oral radiology，and endodontics，2003，95（6）：710-716.
72.Caino MC，Lopez-Haber C，Kim J，et al. Proteins kinase Cvarepsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene，2012，31（20）：2593-2600.
73.Caino MC，Meshki J，Kazanietz MG.Hallmarks for senescence in carcinogenesis：novel signaling players. Apoptosis，2009，14（4）：392-408.
74.Oliva JL，Caino MC，Senderowicz AM，et al.S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells.J Biol Chem，2008，283（9）：5466-5476.
75.Bae KM，Wang H，Jiang G，et al. Protein kinase C epsilon is over expressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner.Cancer Res，2007，67（13）：6053-6063.
76.Basu A，Sivaprasad U.Protein kinase Cepsilon makes the life and death decision. Cell Signal，2007，19（8）：1633-1642.
77.Felber M，Sonnemann J，Beck JF. Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells.Pathol Oncol Res，2007，13（4）：295-301.
78.Gorin MA，Pan Q.Protein kinase C epsilon：an oncogene and emerging tumor biomarker.Mol Cancer，2009，8：9.
79.Caino MC，Lopez-Haber C，Kissil JL，et al.Non-small cell lung carcinoma cell motility，rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS One，2012，7（2）：e31714.
80.Hong SH，Ren L，Mendoza A，et al. Apoptosis resistance and PKC signaling：distinguishing features of high and low metastatic cells. Neoplasia，2012，14（3）：249-258.
81.Gao ZQ，Han BH，Sha HF，et al.Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer.Zhonghua Jie He He Hu Xi Za Zhi.2010，33（4）：284-288.
82.Bowling N，Walsh RA，Song G，et al.Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.Circulation，1999，99（3）：384-391.
83.Nishikawa T，Edelstein D，Brownlee M.The missing link：a single unifying mechanism for diabetic complications. Kidney Int Suppl，2000，77：S26-30.
84.Podar K，Raab MS，Chauhan D，et al.The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs，2007，16（10）：1693-1707.
85.Ali AS，Ali S，El-Rayes BF，et al. Exploitation of protein kinase C：a useful target for cancer therapy.Cancer Treat Rev，2009，35（1）：1-8.
86.Reyland ME.Protein kinase C isoforms：Multi-functional regulators of cell life and death. Frontiers in bioscience（Landmark edition），2009，14：2386-2399.
87.Bosco R，Melloni E，Celeghini C，et al. Fine tuning of protein kinase C（PKC） isoforms in cancer：shortening the distance from the laboratory to the bedside.Mini Rev Med Chem，2011，11（3）：185-199.
88.DiazGranados N，Zarate CA Jr.A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep，2008，10（6）：510-519.
89.Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res，2006，12（18）：5336-5345.
90.Budas GR，Churchill EN，Mochly-Rosen D.Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury.Pharmacol Res，2007，55（6） 523-536.
91.Pravdic D，Sedlic F，Mio Y，et al.Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein Kinase C-epsilon-mediated pathway.Anesthesiology，2009，111（2）：267-274.
92.Ding RQ，Tsao J，Chai H，et al. Therapeutic potential for protein kinase C inhibitor in vascular restenosis. J Cardiovasc Pharmacol Ther，2011，16（2）：160-167.
93.Pang X，Sun NL. Calcineurin-NFAT signaling is involved in phenylephrine-induced vascular smooth muscle cell proliferation. Acta Pharmacol Sin，2009，30（5）：537-544.
94.Mochly-Rosen D，Das K，Grimes KV. Protein kinase C，an elusive therapeutic target.Nat Rev Drug Discov，2012，11（12）：937-957.
95.Socinski MA，Raju RN，Stinchcombe T，et al. Randomized，phase Ⅱ trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage ⅢB/Ⅳ nonsmall cell lung cancer. J Thorac Oncol，2010，5（12）：1963-1969.
96.Carducci MA，Musib L，Kies MS，et al. Phase Ⅰ dose escalation and pharmacokinetic study of enzastaurin，an oral protein kinase C beta inhibitor，in patients with advanced cancer. J Clin Oncol，2006，24（25）：4092-4099.
97.Hanauske AR，Oberschmidt O，Hanauske-Abel H，et al. Antitumor activity of enzastaurin（LY317615.HCl）against human cancer cell lines and freshly explanted tumors investigated in in-vitro ［corrected］ soft-agar cloning experiments. Invest New Drugs，2007，25（3）：205-210.
98.Korner A，Mudduluru G，Manegold C，et al. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer，2010，103（6）：802-811.
99.Willey CD，Xiao D，Tu T，et al. Enzastaurin（LY317615），a protein kinase C beta selective inhibitor，enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys，2010，77（5）：1518-1526.
100.Ma S，Rosen ST. Enzastaurin. Curr Opin Oncol，2007，19（6）：590-595.
101.Robertson MJ，Kahl BS，Vose JM，et al. PhaseⅡ study of enzastaurin，a protein kinase C beta inhibitor，in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol，2007，25（13）：1741-1746.
102.Meng XW，Heldebrant MP，Flatten KS，et al. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation：a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem，2010，285（2）：888-902.
103.Ruvolo PP，Zhou L，Watt JC，et al. Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem. 2011，112（6）：1696-707.
104.Wang Y，Yang H，Liu H，et al. Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells：an in vitro study. BMC Cancer，2009，9：174.
105.Entschladen F，Drell TL 4th，Lang K，et al. Neurotransmitters and chemokines regulate tumor cell migration：potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des，2005，11（3）：403-411.
106.Zhang YX，Yu SB，Ou-Yang JP，et al. Effect of protein kinase C alpha，caspase-3，and survivin on apoptosis of oral cancer cells induced by staurosporine. Acta Pharmacol Sin，2005，26（11）：1365-1372.
107.Mackay HJ，Twelves CJ. Targeting the protein kinase C family：are we there yet. Nat Rev Cancer，2007，7（7）：554-562.
108.Rini BI，Weinberg V，Shaw V，et al. Time to disease progression to evaluate a novel protein kinase C inhibitor，UCN-01，in renal cell carcinoma. Cancer，2004，101（1）：90-95.
109.Welch S，Hirte HW，Carey MS，et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer：a study of the Princess Margaret Hospital Phase Ⅱ consortium. Gynecol Oncol，2007，106（2）：305-310.
110.Kim YM，Jeong IH，Pyo H. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine（UCN-01）in human lung cancer cell lines. Int J Radiat Oncol Biol Phys，2012，83（3）：e399-407.
111.Hewson CA，Edbrooke MR，Johnston SL. PMA induces the MUC5AC respiratory mucin in human bronchial epithelial cells，via PKC，EGF/TGF-alpha，Ras/Raf，MEK，ERK and Sp1-dependent mechanisms. J Mol Biol，2004，344（3）：683-695.
112.Stahl S，Kaminskyy VO，Efazat G，et al. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.Cell Death Dis，2013，4：e454.
113.Robins HI，Won M，Seiferheld WF，et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme：RTOG protocol BR-0021.Neuro Oncol，2006，8（1）：47-52.
114.Philip PA，Rea D，Thavasu P，et al. Phase I study of bryostatin 1：assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase Ⅰ Committee. J Natl Cancer Inst，1993，85（22）：1812-1818.
115.Lam AP，Sparano JA，Vinciguerra V，et al. Phase Ⅱ study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol，2010，33（2）：121-124.
116.Nezhat F，Wadler S，Muggia F，et al. Phase Ⅱ trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix：a New York Gynecologic Oncology Group study. Gynecol Oncol，2004，93（1）：144-148.
117.Ku GY，Ilson DH，Schwartz LH，et al. Phase Ⅱ trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol，2008，62（5）：875-880.
118.Ajani JA，Jiang Y，Faust J，et al. A multi-center phase Ⅱ study of sequential paclitaxel and bryostatin-1（NSC 339555） in patients with untreated，advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs，2006，24（4）：353-357.
119.Cripps MC，Figueredo AT，Oza AM，et al. Phase Ⅱ randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer：a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res，2002，8（7）：2188-2192.
120.Tolcher AW，Reyno L，Venner PM，et al. A randomized phase Ⅱ and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res，2002，8（8）：2530-2535.
121.Marshall JL，Eisenberg SG，Johnson MD，et al. A phase Ⅱ trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer，2004，4（4）：268-274.
122.Advani R，Lum BL，Fisher GA，et al. A phase Ⅰ trial of aprinocarsen（ISIS 3521/LY900003），an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs，2005，23（5）：467-477.
123.Rao S，Watkins D，Cunningham D，et al. Phase Ⅱ study of ISIS 3521，an antisense oligodeoxynucleotide to protein kinase C alpha，in patients with previously treated low-grade non-Hodgkin’s lymphoma. Annals of oncology：official journal of the European Society for Medical Oncology / ESMO，2004，15（9）：1413-1418.
124.Paz-Ares L，Douillard JY，Koralewski P，et al. Phase Ⅲ study of gemcitabine and cisplatin with or without aprinocarsen，a protein kinase C-alpha antisense oligonucleotide，in patients with advanced-stage non-smallcell lung cancer. J Clin Oncol，2006，24（9）：1428-1434.
125.Gschwendt M，Muller HJ，Kielbassa K，et al. Rottlerin，a novel protein kinase inhibitor. Biochem Biophys Res Commun，1994，199（1）：93-98.
126.Davis MI，Hunt JP，Herrgard S，et al.Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol，2011，29（11）：1046-1051.
127.Halls ML，Cooper DM.Regulation by Ca2+-signaling pathways of adenylyl cyclases. Cold Spring Harb Perspect Biol，2011，3（1）：a004143.